X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ALEMBIC LTD - Comparison Results

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA ALEMBIC LTD ALEMBIC PHARMA/
ALEMBIC LTD
 
P/E (TTM) x 21.9 51.4 42.5% View Chart
P/BV x 5.2 2.2 234.2% View Chart
Dividend Yield % 0.7 0.5 142.2%  

Financials

 ALEMBIC PHARMA   ALEMBIC LTD
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-18
ALEMBIC LTD
Mar-18
ALEMBIC PHARMA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs64572 896.0%   
Low Rs47034 1,385.8%   
Sales per share (Unadj.) Rs166.14.7 3,533.0%  
Earnings per share (Unadj.) Rs21.96.1 358.8%  
Cash flow per share (Unadj.) Rs27.56.2 440.2%  
Dividends per share (Unadj.) Rs4.000.20 2,000.0%  
Dividend yield (eoy) %0.70.4 190.0%  
Book value per share (Unadj.) Rs117.840.7 289.6%  
Shares outstanding (eoy) m188.52267.03 70.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.411.3 29.8%   
Avg P/E ratio x25.58.7 293.4%  
P/CF ratio (eoy) x20.38.5 239.2%  
Price / Book Value ratio x4.71.3 363.5%  
Dividend payout %18.33.3 557.5%   
Avg Mkt Cap Rs m105,09014,139 743.3%   
No. of employees `000NANA-   
Total wages/salary Rs m6,228207 3,002.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m31,3081,255 2,494.3%  
Other income Rs m70370 19.0%   
Total revenues Rs m31,3781,625 1,930.5%   
Gross profit Rs m6,431111 5,788.4%  
Depreciation Rs m1,05538 2,789.9%   
Interest Rs m342 2,000.0%   
Profit before tax Rs m5,413442 1,225.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-811,212 -6.7%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,20424 5,025.1%   
Profit after tax Rs m4,1281,630 253.3%  
Gross profit margin %20.58.9 232.1%  
Effective tax rate %22.25.4 410.2%   
Net profit margin %13.2129.8 10.2%  
BALANCE SHEET DATA
Current assets Rs m18,2471,867 977.3%   
Current liabilities Rs m11,235591 1,900.4%   
Net working cap to sales %22.4101.6 22.0%  
Current ratio x1.63.2 51.4%  
Inventory Days Days8694 90.8%  
Debtors Days Days6174 83.4%  
Net fixed assets Rs m20,0351,791 1,118.7%   
Share capital Rs m377534 70.6%   
"Free" reserves Rs m21,82410,324 211.4%   
Net worth Rs m22,20110,858 204.5%   
Long term debt Rs m5,00041 12,135.9%   
Total assets Rs m39,41111,591 340.0%  
Interest coverage x160.2260.9 61.4%   
Debt to equity ratio x0.20 5,935.1%  
Sales to assets ratio x0.80.1 733.6%   
Return on assets %10.614.1 75.0%  
Return on equity %18.615.0 123.9%  
Return on capital %19.715.2 129.9%  
Exports to sales %46.41.5 3,003.7%   
Imports to sales %10.521.0 50.1%   
Exports (fob) Rs m14,53519 74,921.6%   
Imports (cif) Rs m3,288263 1,248.7%   
Fx inflow Rs m14,72219 75,884.5%   
Fx outflow Rs m7,026264 2,663.1%   
Net fx Rs m7,696-244 -3,148.6%   
CASH FLOW
From Operations Rs m3,124236 1,324.9%  
From Investments Rs m-8,844-224 3,948.1%  
From Financial Activity Rs m5,026-27 -18,895.9%  
Net Cashflow Rs m-693-15 4,684.5%  

Share Holding

Indian Promoters % 74.1 64.0 115.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 0.2 1,450.0%  
FIIs % 9.1 9.7 93.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 26.1 53.3%  
Shareholders   49,328 54,701 90.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   PLETHICO PHARMA  BIOCON LTD  FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (2QFY19); Net Profit Up 4.0% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Dec 14, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS